EP2968531A4 - Cellules souches cancéreuses ovariennes de haute pureté pour immunothérapie autologue active - Google Patents

Cellules souches cancéreuses ovariennes de haute pureté pour immunothérapie autologue active

Info

Publication number
EP2968531A4
EP2968531A4 EP14778635.4A EP14778635A EP2968531A4 EP 2968531 A4 EP2968531 A4 EP 2968531A4 EP 14778635 A EP14778635 A EP 14778635A EP 2968531 A4 EP2968531 A4 EP 2968531A4
Authority
EP
European Patent Office
Prior art keywords
cancer
high purity
strains
ovarian cancer
autologous immunotherapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14778635.4A
Other languages
German (de)
English (en)
Other versions
EP2968531A1 (fr
Inventor
Andrew N Cornforth
Gabriel Nistor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lisata Therapeutics Inc
Original Assignee
NeoStem Oncology LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2013/053850 external-priority patent/WO2014028274A1/fr
Application filed by NeoStem Oncology LLC filed Critical NeoStem Oncology LLC
Publication of EP2968531A1 publication Critical patent/EP2968531A1/fr
Publication of EP2968531A4 publication Critical patent/EP2968531A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Microbiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP14778635.4A 2013-03-12 2014-03-10 Cellules souches cancéreuses ovariennes de haute pureté pour immunothérapie autologue active Withdrawn EP2968531A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361778225P 2013-03-12 2013-03-12
PCT/US2013/053850 WO2014028274A1 (fr) 2012-08-15 2013-08-06 Procédé de production rapide de cellules souches cancéreuses de pureté élevée et d'une population de cellules souches cancéreuses de pureté élevée
PCT/US2014/022494 WO2014164464A1 (fr) 2013-03-12 2014-03-10 Cellules souches cancéreuses ovariennes de haute pureté pour immunothérapie autologue active

Publications (2)

Publication Number Publication Date
EP2968531A1 EP2968531A1 (fr) 2016-01-20
EP2968531A4 true EP2968531A4 (fr) 2016-12-28

Family

ID=51658876

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14778635.4A Withdrawn EP2968531A4 (fr) 2013-03-12 2014-03-10 Cellules souches cancéreuses ovariennes de haute pureté pour immunothérapie autologue active

Country Status (8)

Country Link
EP (1) EP2968531A4 (fr)
JP (1) JP2016512423A (fr)
KR (1) KR20150139529A (fr)
CN (1) CN105339000A (fr)
AU (1) AU2014249346A1 (fr)
CA (1) CA2905288A1 (fr)
HK (1) HK1220616A1 (fr)
WO (1) WO2014164464A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016081554A1 (fr) * 2014-11-18 2016-05-26 Neostem Oncology, Llc Compositions immunogènes préparées à partir de cellules tumorales dérivées du sang périphérique et provenant d'une tumeur solide et leur utilisation
US10472599B2 (en) 2015-01-07 2019-11-12 Dana-Farber Cancer Institute, Inc. Microfluidic cell culture of patient-derived tumor cell spheroids
US11464838B2 (en) * 2015-04-01 2022-10-11 Colorado State University Research Foundation Optimized cancer stem cell vaccines
GB201609663D0 (en) * 2016-06-02 2016-07-20 Stemtek Therapeutics Sl Methods for producing cancer stem cell spheroids
EP3600425A4 (fr) 2017-03-31 2020-12-23 Dana-Farber Cancer Institute, Inc. Procédés d'évaluation de sphéroïdes de cellules tumorales à l'aide d'un dispositif de culture cellulaire microfluidique 3d
CN110623982B (zh) * 2019-09-23 2023-04-25 四川大学华西医院 卵巢表面上皮细胞的3d-emt免疫活性制剂及制备与应用
CN112618712A (zh) * 2021-01-21 2021-04-09 武汉轻工大学 一种含波形蛋白的佐剂及应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080206286A1 (en) * 2006-09-26 2008-08-28 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
US20110313229A1 (en) * 2008-07-24 2011-12-22 Kiminobu Sugaya Therapy Targeting Cancer Stem Cells
WO2012167101A1 (fr) * 2011-06-03 2012-12-06 The General Hospital Corporation Cellules souches du cancer de l'ovaire et procédés d'isolement et utilisations associés
WO2014127276A1 (fr) * 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Vaccins contre le cancer ovarien et méthodes de vaccination

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008067408A2 (fr) * 2006-11-28 2008-06-05 Cedars-Sinai Medical Center Procédé d'isolement et de propagation de cellules souches provenant de tumeurs bénignes
EP2190481B1 (fr) * 2007-07-17 2014-12-24 The General Hospital Corporation Methodes d'identification et d'enrichissement de populations de cellules souches cancereuses ovariennes et de cellules souches somatiques ovariennes et utilisations associees
WO2010124498A1 (fr) * 2009-04-30 2010-11-04 Beijing Cellonis Biotechnology Co., Ltd Cellule-souche tumorale dont la résistance a été criblée, sa composition antigénique, le chargement de cellules dendritiques antitumorales avec lesdits antigènes, leurs méthodes de préparation, utilisations et kits ainsi qu'un vaccin à base de cellules dendritiques
CN101560496A (zh) * 2009-04-30 2009-10-21 北京弘润天源生物技术有限公司 经耐受性筛选的肿瘤干细胞抗原负载的树突状细胞，其制法、应用、试剂盒及包括其的疫苗
CN102770530A (zh) * 2009-11-05 2012-11-07 斯隆-凯特林癌症研究院 自由漂浮链：浆膜癌干细胞
CA2882095A1 (fr) * 2012-08-15 2014-02-20 Andrew CORNFORTH Procede de production rapide de cellules souches cancereuses de purete elevee et d'une population de cellules souches cancereuses de purete elevee

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080206286A1 (en) * 2006-09-26 2008-08-28 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
US20110313229A1 (en) * 2008-07-24 2011-12-22 Kiminobu Sugaya Therapy Targeting Cancer Stem Cells
WO2012167101A1 (fr) * 2011-06-03 2012-12-06 The General Hospital Corporation Cellules souches du cancer de l'ovaire et procédés d'isolement et utilisations associés
WO2014127276A1 (fr) * 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Vaccins contre le cancer ovarien et méthodes de vaccination

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GORH V ET AL: "Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 102, no. 18, 3 May 2005 (2005-05-03), pages 6461 - 6466, XP008109619, ISSN: 0027-8424, DOI: 10.1073/PNAS.0501953102 *
LOVELAND B E ET AL: "Mannan-MUC1-Pulsed Dendritic Cell Immunotherapy: A Phase I Trial in Patients with Adenocarcinoma", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 12, no. 3, 1 February 2006 (2006-02-01), pages 869 - 877, XP008102879, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-05-1574 *
PONNUSAMY MOORTHY P ET AL: "Ovarian cancer: emerging concept on cancer stem cells", JOURNAL OF OVARIAN RESEARCH, BIOMED CENTRAL LTD, LONDON, UK, vol. 1, no. 1, 12 October 2008 (2008-10-12), pages 4, XP021046393, ISSN: 1757-2215, DOI: 10.1186/1757-2215-1-4 *
SANTIN A D ET AL: "IN VITRO INDUCTION OF TUMOR-SPECIFIC HUMAN LYMPHOCYTE ANTIGEN CLASS I-RESTRICTED CD8+ CYTOTOXIC T LYMPHOCYTES BY OVARIAN TUMOR ANTIGEN-PULSED AUTOLOGOUS DENDRITIC CELLS FROM PATIENTS WITH ADVANCED OVARIAN CANCER", AMERICAN JOURNAL OF OBSTETRICS & GYNECOLOGY, MOSBY, ST LOUIS, MO, US, vol. 183, 1 January 2000 (2000-01-01), pages 601 - 609, XP001010219, ISSN: 0002-9378, DOI: 10.1067/MOB.2000.107097 *
See also references of WO2014164464A1 *

Also Published As

Publication number Publication date
HK1220616A1 (zh) 2017-05-12
AU2014249346A8 (en) 2015-10-15
EP2968531A1 (fr) 2016-01-20
CA2905288A1 (fr) 2014-10-09
CN105339000A (zh) 2016-02-17
KR20150139529A (ko) 2015-12-11
AU2014249346A1 (en) 2015-10-01
WO2014164464A1 (fr) 2014-10-09
JP2016512423A (ja) 2016-04-28

Similar Documents

Publication Publication Date Title
EP3079707A4 (fr) Immunothérapie du cancer
IL245725A0 (en) A method for engineering t cells that are resistant to chemotherapy drugs, for use in immunotherapy
EP3090066A4 (fr) Déterminants de la réponse d'un cancer à l'immunothérapie
HRP20190460T1 (hr) Postupak proizvodnje endotelnih stanica rožnice usmjerenom diferencijacijom
HUE046414T2 (hu) Eljárás tagatóz elõállítására
PT3083694T (pt) Anticorpos murinos caninizados anti-pd-1 canino
EP3192305A4 (fr) Wifi rapide pour transfert lte
DK3164414T3 (da) Antistoffer for IL-15
EP2948531A4 (fr) Compositions de matières de biomasse pour le raffinage
ZA201509334B (en) Improved process for production of monoclonal antibodies
EP2968531A4 (fr) Cellules souches cancéreuses ovariennes de haute pureté pour immunothérapie autologue active
DK3010352T3 (da) Fremgangsmåde til fremstilling af fodertilsætning
EP3135671A4 (fr) Nouveau cristal de composé tétracyclique
EP3291821A4 (fr) Immunothérapie par cellules dendritiques
ZA201604296B (en) Synthesis of zsm-48 crystals
EP2966053A4 (fr) 2-fluorobutane de pureté élevée
EP3052630A4 (fr) Micro-organisme recombiné pour une production améliorée de produits chimiques fins
FR3006316B1 (fr) Composition de poudres de polyarylene-ether-cetone-cetone adaptees au frittage laser
EP3080273A4 (fr) Micro-organisme recombinant pour la production améliorée de produits chimiques fins
EP3003372A4 (fr) Inhibiteurs du facteur h du complément
SG11201604701PA (en) Novel anti-agglomerants for polyisobutylene production
EP3123173A4 (fr) Méthodes de suppression du cancer par inhibition de tmcc3
EP3011013A4 (fr) Procédé pour le traitement d'un cancer de l'ovaire
EP3039894A4 (fr) Transfert de profil zeroconf pour permettre l'itinérance rapide
GB201303491D0 (en) Culture of leukemia initiating cells

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150925

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20161130

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/18 20060101ALI20161124BHEP

Ipc: A61K 38/19 20060101ALI20161124BHEP

Ipc: A61K 39/395 20060101ALI20161124BHEP

Ipc: A61K 35/13 20150101ALI20161124BHEP

Ipc: A61K 35/15 20150101ALI20161124BHEP

Ipc: A61K 35/12 20060101AFI20161124BHEP

Ipc: A61K 39/00 20060101ALI20161124BHEP

Ipc: A61K 39/39 20060101ALI20161124BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1220616

Country of ref document: HK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CALADRIUS BIOSCIENCES, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20191001

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1220616

Country of ref document: HK